Novartis Withdraws Arzerra CLL Second-Line Use Filing in EU
Executive Summary
Novartis has withdrawn its label extension application in Europe for use of Arzerra in combination with bendamustine for the treatment of relapsed chronic lymphocytic leukemia, following CHMP queries over a lack of comparable data.
You may also be interested in...
Imbruvica Leads Sea Change In CLL Landscape
Johnson & Johnson/AbbVie Inc. 's Imbruvica (ibrutinib) has rapidly established itself as standard of care in relapsed/refractory chronic lymphocytic leukaemia and will increasingly move into the first-line setting following its recent approval by the FDA for that use in patients with CLL, analysts say.
Novartis Sees Real Value Of Ofatumumab In MS, Pays GSK Up To $1Bn
GlaxoSmithKline is divesting its rights in ofatumumab in autoimmune indications, including multiple sclerosis, to Novartis. Novartis previously acquired the oncology rights for ofatumumab (marketed as Arzerra) as part of the major three-part transaction between the companies. It now holds complete rights to the fully human CD20-targeting monoclonal antibody.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.